| P50 | author | Manuela Donalisio | Q88409754 |
| | Andrea Civra | Q127278674 |
| P2093 | author name string | David Lembo | |
| | Monica Argenziano | |
| | Roberta Cavalli | |
| P2860 | cites work | Herpes Simplex | Q22305953 |
| | Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability | Q24628212 |
| | The Smart Drug Delivery System and Its Clinical Potential | Q26744837 |
| | Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials | Q26745783 |
| | Magnetic nanotherapeutics for dysregulated synaptic plasticity during neuroAIDS and drug abuse | Q26746336 |
| | Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application | Q26778603 |
| | Nanostructures for the Inhibition of Viral Infections | Q26801513 |
| | Magnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriers | Q27317660 |
| | Approved Antiviral Drugs over the Past 50 Years | Q27755387 |
| | Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus | Q28067143 |
| | The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials | Q28087336 |
| | HIV-AIDS: much accomplished, much to do. | Q30354779 |
| | Nanotechnology and HIV: potential applications for treatment and prevention | Q30393980 |
| | Physical energy for drug delivery; poration, concentration and activation. | Q30412855 |
| | Enhanced antiviral activity of Acyclovir loaded into beta-cyclodextrin-poly(4-acryloylmorpholine) conjugate nanoparticles | Q33429296 |
| | Formulation and transport properties of tenofovir loaded liposomes through Caco-2 cell model | Q45366387 |
| | Novel nanoparticles made from amphiphilic perfluoroalkyl alpha-cyclodextrin derivatives: preparation, characterization and application to the transport of acyclovir. | Q45989946 |
| | Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. | Q46017927 |
| | Mucoadhesive tablets for controlled release of acyclovir | Q46267671 |
| | Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir | Q46567295 |
| | Preparation and in vitro evaluation of the antiviral activity of the Acyclovir complex of a beta-cyclodextrin/poly(amidoamine) copolymer. | Q46851134 |
| | Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method. | Q46907206 |
| | Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity | Q47792257 |
| | Self-assembled drug delivery systems. Part 7: hepatocyte-targeted nanoassemblies of an adefovir lipid derivative with cytochrome P450-triggered drug release | Q47998338 |
| | Tissue distribution of borneol-modified ganciclovir-loaded solid lipid nanoparticles in mice after intravenous administration | Q48271556 |
| | Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. | Q48284053 |
| | Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier | Q48434506 |
| | Mucoadhesive thermo-responsive chitosan-g-poly(N-isopropylacrylamide) polymeric micelles via a one-pot gamma-radiation-assisted pathway | Q48643021 |
| | Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier | Q48822708 |
| | The physics of drug-delivery across the blood-brain barrier. | Q48893237 |
| | Preparation and evaluation of zanamivir-loaded solid lipid nanoparticles. | Q53393632 |
| | The mechanism of the opening of the blood-brain barrier by borneol: A pharmacodynamics and pharmacokinetics combination study. | Q53623109 |
| | In-vitro release of acyclovir loaded Eudragit RLPO(®) nanoparticles for sustained drug delivery. | Q54587412 |
| | Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery | Q39454723 |
| | Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles | Q39517460 |
| | pH-sensitive Eudragit nanoparticles for mucosal drug delivery | Q39640640 |
| | Phytoliposome-Based Silibinin Delivery System as a Promising Strategy to Prevent Hepatitis C Virus Infection. | Q39684075 |
| | Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. | Q40158060 |
| | Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer | Q40184020 |
| | Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages | Q40206907 |
| | Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits. | Q40478874 |
| | Antivirals for the treatment of herpesvirus infections | Q40863347 |
| | Ring-opening polymerization of ε-caprolactone initiated by ganciclovir (GCV) for the preparation of GCV-tagged polymeric micelles. | Q41487730 |
| | Optimisation of multiple W/O/W nanoemulsions for dermal delivery of aciclovir | Q41614444 |
| | Co-delivery of antiviral and antifungal therapeutics for the treatment of sexually transmitted infections using a moldable, supramolecular hydrogel | Q41734228 |
| | Cyclodextrin-based nanosponges as drug carriers. | Q41903071 |
| | Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells | Q41951619 |
| | Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time | Q41989031 |
| | Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes | Q41989355 |
| | Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. | Q42108498 |
| | Preparation, characterization and in vitro antiviral activity evaluation of foscarnet-chitosan nanoparticles. | Q42223838 |
| | Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting | Q42262319 |
| | Synthesis of lamivudine stearate and antiviral activity of stearic acid-g-chitosan oligosaccharide polymeric micelles delivery system | Q42930395 |
| | Preparation and characterization of niosomes containing ribavirin for liver targeting | Q43115879 |
| | Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. | Q43213058 |
| | Yak interferon-alpha loaded solid lipid nanoparticles for controlled release | Q43300669 |
| | Influenza hemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection. | Q43484267 |
| | Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. | Q43748771 |
| | Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir | Q43811991 |
| | Drug-induced nanocarrier assembly as a strategy for the cellular delivery of nucleotides and nucleotide analogues. | Q44263134 |
| | AZT 5'-triphosphate nanoformulation suppresses human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells | Q44292281 |
| | Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin | Q44415253 |
| | Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles | Q44417706 |
| | Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir | Q44506744 |
| | Submicron-size biodegradable polymer-based didanosine particles for treating HIV at early stage: an in vitro study | Q44538207 |
| | Design, synthesis, and in vitro evaluation of new amphiphilic cyclodextrin-based nanoparticles for the incorporation and controlled release of acyclovir | Q45213842 |
| | Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. | Q38788187 |
| | Design and fabrication of hydrogel-based nanoparticulate systems for in vivo drug delivery | Q38799207 |
| | Recent trends on hydrogel based drug delivery systems for infectious diseases | Q38810357 |
| | Nano-ART and NeuroAIDS. | Q38823456 |
| | Smart nanoparticles as targeting platforms for HIV infections. | Q38887077 |
| | Nanomedicines: From Bench to Bedside and Beyond. | Q38915184 |
| | Development of biodegradable nanoparticles for liver-specific ribavirin delivery | Q38946029 |
| | The immune system of the gut and potential adverse effects of oral nanocarriers on its function | Q38969781 |
| | Auto-associative heparin nanoassemblies: a biomimetic platform against the heparan sulfate-dependent viruses HSV-1, HSV-2, HPV-16 and RSV. | Q38994405 |
| | Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art. | Q39004638 |
| | Insight into the interactions between nanoparticles and cells | Q39034160 |
| | Novel functionalization strategies of polymeric nanoparticles as carriers for brain medications | Q39154878 |
| | Novel composed galactosylated nanodevices containing a ribavirin prodrug as hepatic cell-targeted carriers for HCV treatment | Q39383819 |
| | Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes | Q39429354 |
| | Enhanced oral bioavailability of efavirenz by solid lipid nanoparticles: in vitro drug release and pharmacokinetics studies. | Q33747638 |
| | Emerging nanotechnology approaches for HIV/AIDS treatment and prevention | Q33819656 |
| | Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation | Q33826308 |
| | HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. | Q33900441 |
| | Glycan-protein interactions in viral pathogenesis | Q33926161 |
| | Insight into nanoparticle cellular uptake and intracellular targeting | Q34127625 |
| | Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice | Q34138487 |
| | Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket | Q34298481 |
| | Optimal structural design of mannosylated nanocarriers for macrophage targeting. | Q34623115 |
| | Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. | Q34728884 |
| | Immunogenicity of two FMDV nonameric peptides encapsulated in liposomes in mice and the protective efficacy in guinea pigs | Q34850165 |
| | Sustained-release nanoART formulation for the treatment of neuroAIDS | Q35082009 |
| | Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons | Q35145361 |
| | Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles | Q35147145 |
| | Enhanced dermal delivery of acyclovir using solid lipid nanoparticles | Q35580996 |
| | HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective | Q35698144 |
| | Nanotechnology and the treatment of HIV infection. | Q35943647 |
| | Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application | Q35947035 |
| | Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue. | Q36093283 |
| | Preparation of bioactive interferon alpha-loaded polysaccharide nanoparticles using a new approach of temperature-induced water phase/water-phase emulsion | Q36228386 |
| | Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza A virus | Q36708487 |
| | Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity | Q36875347 |
| | Overcoming pharmacologic sanctuaries | Q36915933 |
| | Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment | Q36934918 |
| | Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. | Q37013364 |
| | Nanotechnology: a focus on nanoparticles as a drug delivery system | Q37015442 |
| | Enhancing intestinal drug solubilisation using lipid-based delivery systems. | Q37044115 |
| | Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus | Q37280337 |
| | Targeting anti-HIV drugs to the CNS. | Q37368323 |
| | Niosomes in sustained and targeted drug delivery: some recent advances. | Q37618808 |
| | Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. | Q37632861 |
| | Nanotechnology applications for improved delivery of antiretroviral drugs to the brain | Q37633076 |
| | Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. | Q37639557 |
| | Nanoparticulate delivery systems for antiviral drugs | Q37812222 |
| | Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances | Q37818332 |
| | Cellular interactions of therapeutically delivered nanoparticles | Q37827166 |
| | Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution | Q37943601 |
| | Safety assessment of nanomaterials: implications for nanomedicine. | Q37981481 |
| | Nanoparticles-mediated drug delivery approaches for cancer targeting: a review | Q38032893 |
| | Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system | Q38038897 |
| | Potentials and challenges in self-nanoemulsifying drug delivery systems | Q38041256 |
| | Nanomedicines for treatment of viral diseases | Q38091127 |
| | HIV integrase inhibitors: 20-year landmark and challenges | Q38124090 |
| | A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach. | Q38149966 |
| | Stimuli-responsive nanocarriers for drug delivery. | Q38154805 |
| | Strategies for improving mucosal drug delivery | Q38166442 |
| | Nanotechnology: a magic bullet for HIV AIDS treatment | Q38190581 |
| | An overview of antiretroviral pre-exposure prophylaxis of HIV infection | Q38196410 |
| | Nano-niosomes as nanoscale drug delivery systems: an illustrated review | Q38205697 |
| | Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications | Q38226315 |
| | Targeting strategies for delivery of anti-HIV drugs | Q38239575 |
| | Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs | Q38260862 |
| | Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect | Q38425256 |
| | Improving bioavailability and biodistribution of anti-HIV chemotherapy. | Q38456541 |
| | Ligand-Appended BBB-Targeted Nanocarriers (LABTNs). | Q38467695 |
| | Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations | Q38470559 |
| | Cyclodextrin complexes for treatment improvement in infectious diseases | Q38501664 |
| | Formulation and pharmacology of long-acting rilpivirine | Q38518429 |
| | Long-acting antiviral agents for HIV treatment | Q38518438 |
| | Cabotegravir long-acting for HIV-1 prevention | Q38518446 |
| | Nanoneurotherapeutics approach intended for direct nose to brain delivery. | Q38522125 |
| | Nanomedicine for Infectious Disease Applications: Innovation towards Broad-Spectrum Treatment of Viral Infections. | Q38628767 |
| | Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them | Q38697972 |
| | Current applications of nanoparticles in infectious diseases. | Q38698207 |
| | Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy | Q38750666 |
| | Size- and coating-dependent cytotoxicity and genotoxicity of silver nanoparticles evaluated using in vitro standard assays | Q38756699 |
| | Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. | Q38761022 |
| | Polymeric mixed micelles as nanomedicines: Achievements and perspectives | Q38770572 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanomedicine | Q261659 |
| P304 | page(s) | 1-22 | |
| P577 | publication date | 2017-07-27 | |
| P1433 | published in | Expert Opinion on Drug Delivery | Q5421203 |
| P1476 | title | Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections | |